OCTRONIS 1 100MCG/ML | MedicScientist :: Total Health Portal

The Brand Name OCTRONIS Has Generic Salt :: Octreotide 

OCTRONIS  Is From Company NEISS Priced :: Rs. 390

OCTRONIS have Octreotide is comes under Sub class Pituitary Hormones,Gonadotropins of  Main Class Endocrine,Steroid Hormones , Metabolic System

Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System  Sub Medicine Class :: Pituitary Hormones,Gonadotropins 

 Salt Name :  OR Generic Name Form Price : MRP /Probable Packing
Octreotide  VIAL  Rs. 390  1
Brand Name Company / Manufacturers Strength Unit Price / 1
 OCTRONIS  NEISS  100MCG/ML  1 Rs. 390

Company  Brand Name  Salt Combination Main Medical Class Sub Medical Class
 From NEISS :: OCTRONIS  Octreotide  Endocrine,Steroid Hormones , Metabolic System Pituitary Hormones,Gonadotropins

Indications for Drugs ::

Acromegaly, Variceal haemorrhage, Secretory neoplasms, Following pancreatic surgery, HIV-associated diarrhoea

Drug Dose ::

Adult: IV Variceal haemorrhage in patients w/ cirrhosis 25 mcg/hr for 48 hr (up to 5 days in patients at high risk of re-bleeding). IM Acromegaly Following initial control w/ SC therapy: Depot Initial: 20 mg 4 wkly. Adjust if required after 3 mth to 10-30 mg 4 wkly. Max: 40 mg 4 wkly. IM/SC Secretory neoplasms As SC: Initial: 50 mcg 1-2 times/day, up to 600 mcg/day in 2-4 divided doses based on response. Maintenance: Depot 10-30 mg 4 wkly via IM inj. SC Acromegaly Initial: 50 mcg 3 times/day, increase if needed. Usual dose: 100-200 mcg 3 times/day. Max: 500 mcg 3 times/day. Prevention of complications following pancreatic surgery 100 mcg 3 times/day of a rapid-acting preparation for 7 days, starting at least 1 hr pre-op. HIV-associated diarrhoea Initial: 100 mcg 3 times/day. If symptoms are not controlled after 1 wk, increase to 250 mcg 3 times/day. Secretory neoplasms Initial: 50 mcg 1-2 times/day, up to 600 mcg/day in 2-4 divided doses based on response.

Contraindication ::

Hypersensitivity.

Drug Precautions ::

Renal disease; risk of gall bladder disease; DM; hypothyroidism. Pregnancy, lactation, children, elderly. Monitor levels of vitamin B12 during long term therapy.

Drug Side Effects ::

Local pain, stinging, tingling at site of inj; anorexia, nausea, vomiting, abdominal pain, bloating, flatulence, loose stools, steatorrhoea; biliary tract abnormalities. Hypoglycaemia and hyperglycaemia, hypothyroidism, cardiac conduction abnormalitles, pancreatitis.

Pregnancy category ::
Pregnancy category

2

Drug Mode of Action ::  

Octreotide is a synthetic analogue of somatostatin which acts by suppressing basal and stimulated secretion of growth hormone (GH). It also suppresses LH response to gonadotrophin-releasing hormone and reduces the secretion of gastrin, vasoactive intestinal peptide (VIP), insulin, glucagon, secretin, motilin and pancreatic polypeptide.

Drug Interactions ::

Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, ?-blockers, diuretics. May increase concentration of bromocriptine. Potentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.

 

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.